News & Updates
Filter by Specialty:

COVID-19 vaccination possibly linked to menstrual abnormalities
A high incidence of menstrual disorders among women aged ≤54 years has been noted following COVID-19 vaccination, reveals a Netherlands study. Analysis of spontaneous reports supports this observation.
COVID-19 vaccination possibly linked to menstrual abnormalities
14 Oct 2023
Water vapor thermal therapy for moderate, severe BPH offers most bang for the buck
In the treatment of moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore, water vapor thermal therapy (WVTT) is more cost effective than medical management (MM) in the first-line setting based on the common willingness-to-pay threshold of SGD 50,000 per quality-adjusted life-years (QALYs), a study has found.
Water vapor thermal therapy for moderate, severe BPH offers most bang for the buck
14 Oct 2023
Free PSA improves prediction of prostate cancer
Adding percent free prostate-specific antigen (PSA) to total PSA results in better prediction of clinically significant prostate cancer and fatal prostate cancer in men, reports a study.
Free PSA improves prediction of prostate cancer
13 Oct 2023
Understanding the effects of LDL-C lowering on several diseases
Genetic evidence confirms both the positive and negative associations of low-density lipoprotein cholesterol (LDL-C) reduction with certain metabolic and cardiovascular diseases (CVDs), according to the results of a Mendelian randomization (MR) study in the UK Biobank.
Understanding the effects of LDL-C lowering on several diseases
13 Oct 2023
Ambient PM2.5 linked to TB reactivation in the elderly
A spatio-temporal analysis by researchers from The Chinese University of Hong Kong finds significant associations between high ambient particulate matter (PM)2.5 concentration and increased rates of pulmonary tuberculosis (TB) among the elderly.
Ambient PM2.5 linked to TB reactivation in the elderly
13 Oct 2023
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.